The gastrin-releasing peptide receptor as a therapeutic target in central nervous system disorders

Recent Patents on CNS Drug Discovery

Volumn 2, Issue 2, 2007, Pages 125-129

  Roesler, Rafael ^a   Kapczinski, Flávio ^a   Quevedo, João ^b   Dal Pizzol, Felipe ^b   Schwartsmann, Gilberto ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

Author keywords

Bombesin like peptides; Gastrin releasing peptide; Gastrin releasing peptide receptor; Neurological disorders; Neuropeptides

Indexed keywords

BOMBESIN; BOMBESIN ANTAGONIST; BOMBESIN RECEPTOR; BOMBESIN[6-13][6 DEXTRO PENTAFLUOROPHENYLALANINE 11 DEXTRO ALANINE] METHYL ESTER; G PROTEIN COUPLED RECEPTOR; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE DERIVATIVE; GASTRIN RELEASING PEPTIDE RECEPTOR; GASTRIN RELEASING PEPTIDE RECEPTOR AGONIST; GASTRIN RELEASING PEPTIDE RECEPTOR ANTAGONIST; RC 3095; UNCLASSIFIED DRUG;

BRAIN DISEASE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG SYNTHESIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PATENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR BINDING; REVIEW; UNSPECIFIED SIDE EFFECT;

AMINO ACID SEQUENCE; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; GASTRIN-RELEASING PEPTIDE; HUMANS; MICE; MOLECULAR SEQUENCE DATA; RECEPTORS, BOMBESIN; SIGNAL TRANSDUCTION;

EID: 34250786168     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488907780832742     Document Type: Review

References (71)

1. Moody TW, Merali Z. Bombesin-like peptides and associated receptors within the brain: distribution and behavioral implications. Peptides 2004; 25: 511-20.
2. Ohki-Hamazaki H, Iwabuchi M, Maekawa F. Development and function of bombesin-like peptides and their receptors. Int J Dev Biol 2005; 49: 293-300.
3. Patel O, Shulkes A, Baldwin GS. Gastrin-releasing peptide and cancer. Biochim. Biophys Acta 2006; 1766: 23-41.
4. Roesler R, Henriques JAP, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurological disorders. CNS Neurol Disord Drug Targets 2006; 5: 197-204.
5. Moody TW, Pert CB, Rivier J, Brown MR. Bombesin: specific binding to rat brain membranes. Proc Natl Acad Sci USA 1978; 75: 5372-76.
6. Roesler R, Lessa D, Venturella R, et al. Bombesin/ gastrin-releasing peptide receptors in the basolateral amygdala regulate memory consolidation. Eur J Neurosci 2004; 19: 1041-45.
7. Roesler R, Luft T, Oliveira SH, et al. Molecular mechanisms mediating gastrin-releasing peptide receptor modulation of memory consolidation in the hippocampus. Neuropharmacology 2006; 51: 350-57.
8. Shumyatsky GP, Tsvetkov E, Mallerat G, et al. Identification of a signaling network in lateral nucleus of amygdala important for inhibiting memory specifically related to learned fear. Cell 2002; 111: 905-18.
9. Battey J, Wada E, Corjay M, et al. Molecular genetic analysis of two distinct receptors for mammalian bombesin-like peptides. J Natl Cancer Inst Monogr 1992; 13: 141-44.
10. Battey JF, Way JM, Corjay MH, et al. Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc Natl Acad Sci USA 1991; 88: 395-99.
11. Spindel ER, Giladi E, Brehm P, Goodman RH, Segerson TP. Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor. Mol Endocrinol 1990; 4: 1956-63.
12. Wolf SS, Moody TW. Receptors for GRP/bombesin-like peptides in the rat forebrain. Peptides 1985; 6 Suppl 1: 111-14.
13. Wolf SS, Moody TW, O'Donohue TL, Zarbin MA, Kuhar MJ. Autoradiographic visualization of rat brain binding sites for bombesin-like peptides. Eur J Pharmacol 1983; 87: 163-64.
14. Kamichi S, Wada E, Aoki S, Sekiguchi M, Kimura I, Wada K. Immunohistochemical localization of gastrin-releasing peptide receptor in the mouse brain. Brain Res 2005; 1032: 162-70.
15. Hellmich MR, Ives KL, Udupi V, et al. Multiple protein kinase pathways are involved in gastrin-releasing peptide receptor-regulated secretion. J Biol Chem 1999; 274: 23901-909.
16. Kim HJ, Evers BM, Litvak DA, Hellmich MR, Townsend CM Jr, Signaling mechanisms regulating bombesin-mediated AP-1 gene induction in the human gastric cancer SILA. Am J Physiol Cell Physiol 2000; 279: C326-34.
17. Xiao D, Qu X, Weber HC. Activation of extracellular signal-regulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells. Cell Signal 2003; 15: 945-53.
18. Lee K, Dixon AK, Gonzalez I, et al. Bombesin-like peptides depolarize rat hippocampal interneurones through interaction with subtype 2 bombesin receptors. J Physiol 1999; 518: 791-802.
19. Bissette G, Nemeroff CB, Decker MW, Kizer JS, Agid Y, Javiy-Agid F. Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson's disease. Ann Neurol 1985; 17: 324-28.
20. Gerner RH, van Kammen DP, Ninan PT. Cerebrospinal fluid cholecystokinin, bombesin and somatostatin in schizophrenia and normals. Prog Neuropsychopharmacol Biol Psychiatry 1985; 9: 73-82.
21. Olincy A, Leonard S, Young DA, Sullivan B, Freedman R. Decreased bombesin peptide response to cigarette smoking in schizophrenia. Neuropsychopharmacology 1999; 20: 52-59.
22. Merali Z, McIntosh J, Anisman H. Role of bombesin-related peptides in the control of flood intake. Neuropeptides 1999; 33: 376-86.
23. Frank GK, Kaye WH, Ladenheim EE, McConaha C. Reduced gastrin releasing peptide in cerebrospinal fluid after recovery from bulimia nervosa. Appetite 2001 37: 9-14.
24. Gibson GE, Huang HM. Oxidative stress in Alzheimer's disease. Neurobiol Aging 2005; 26: 575-78.
25. Gibson GE, Vestling M, Zhang H, et al. Abnormalities in Alzheimer's disease fibroblasts bearing the APP670/671 mutation. Neurobiol Aging 1997; 18: 573-80.
26. Gibson GE, Zhang H, Toral-Barza L, Szolosi S, Tofel-Grehl B. Calcium stores in cultured fibroblasts and their changes with Alzheimer's disease. Biochim Biophys Acta 1996; 1316: 71-77.
27. 2+ stores by select oxidants produces changes reminiscent of those in cells from patients with Alzheimer disease. Free Radic Biol Med 2005; 39: 979-989.
28. Ito E, Oka K, Etcheberrigaray R, et al. Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc Natl Acad Sci USA 1994; 91: 534-538.
29. Huang HM, Zhang H, Ou HC, Chen HL, Gibson GE. alpha-keto-beta-methyl-n-valeric acid diminishes reactive oxygen species and alters endoplasmic reticulum Ca(2+) stores. Free Radic Biol Med 2004; 37: 1779-1789.
30. Ishikawa-Brush Y, Powell JF, et al. Autism and multiple exostoses associated with an X;8 translocation occuring within the GRPR gene and 3′ to the SDC2 gene. Hum Mol Genet 1997; 6: 1241-1250.
31. Marui T, Hashimoto O, Namba E, et al. Gastrin-releasing peptide receptor (GRPR) locus in Japanese subjects with autism. Brain Dev 2004; 26: 5-7.
32. Wada E, Watase K, Yamada K, et al. Generation and characterization of mice lacking gastrin-releasing peptide receptor. Biochem. Biophys. Res. Commun 1997; 239: 28-33.
33. Yamada K, Wada E, Wada K. Male mice lacking the gastrin-releasing peptide receptor (GRP-R) display elevated preference for conspecific odors and increased social investigatory behaviors. Brain Res 2000, 870: 20-26.
34. Yamada K, Wada E, Wada K. Female gastrin-releasing peptide receptor (GRP-R)-deficient mice exhibit altered social preference for male conspecifics: implications for GRP/GRP-R modulation of GABAergic function. Brain Res 2001; 894: 281-287.
35. Leissring MA, Akbari Y, Fanger CM, Cahalan MD, Mattson MP, LaFerla FM. Capacitative calcium entry deficits and elevated huminal calcium content in mutant presenilin-1 knockin mice. J Cell Biol 2000; 149: 793-798.
36. Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin M, Mattson MP. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 1999; 5: 101-106.
37. Gmerek DE, Cowan A. Studies on bombesin-induced grooming in rats. Peptides 1983; 4: 907-913.
38. Johnston SA, Merali Z. Specific neuroanatomical and neurochemical correlates of locomotor and grooming effects of bombesin. Peptides 1988; 9 Suppl 1: 245-256.
39. Kulkosky PJ, Gibbs J, Smith GP. Behavioral effects of bombesin administration in rats. Physiol Behav 1992; 28: 505-12.
40. Piggins H, Merali Z. The effects of concurrent D-1 and D-2 dopamine receptor blockade with SCH 23390 and eticlopride, on bombesin-induced behaviours. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 583-94.
41. Merali Z, Kent P, Anisman H. Role of bombesin-related peptides in the mediation or integration of the stress response. Cell Mol Life Sci 2002; 59: 272-87.
42. Gibbs J, Fauser DJ, Rowe EA, Rolls BJ, Rolls ET, Maddison SP. Bombesin suppresses feeding in rats. Nature 1979; 282: 208-10.
43. Taylor IL, Garcia R. Effects of pancreatic polypeptide, caerulein, and bombesin on satiety in obese mice. Am J Physiol 1985; 248: G277-80.
44. Muurahainen NE, Kissileff HR, Pi-Sunyer FX. Intravenous infusion of bombesin reduces food intake in humans. Am J Physiol 1993; 264: R350-4.
45. Flynn FW. Bombesin receptor antagonists block the effects of exogenous bombesin but not of nutrients on food intake. Physiol Behav 1997; 62: 791-98.
46. Flynn FW. Fourth ventricular injection of selective bombesin receptor antagonists facilitates feeding in rats. Am J Physiol 1993; 264: R218-21.
47. Flynn FW. Bombesin-like peptides in the regulation of ingestive behavior. Ann N Y Acad Sci 1994; 739: 120-34.
48. Flood JF, Morley JE. Effects of bombesin and gastrin-releasing peptide on memory processing. Brain Res 1988; 460: 314-22.
49. Williams CL, McGaugh JL. Enhancement of memory processing in an inhibitory avoidance and radial maze task by post-training infusion of bombesin into the nucleus tractus solitarius. Brain Res 1994; 654: 251-56.
50. Roesler R, Meller CA, Kopschina MI, Souza DO, Henriques JA, Schwartsmann G. Intrahippocampal infusion of the bombesin/gastrin-releasing peptide antagonist RC-3095 impairs inhibitory avoidance retention. Peptides 2003; 24: 1069-74.
51. Roesler R, Kopschina MI, Rosa RM, Henriques JA, Souza DO, Schwartsmann G. RC-3095, a bombesin/gastrin-releasing peptide antagonist, impairs aversive but not recognition memory in rats. Eur J Pharmacol 2004; 486: 35-41.
52. Dantas AS, Luft T, Henriques JA, Schwartsmann G, Roesler R. Opposite effects of low and high doses of the gastrin-releasing peptide receptor antagonist RC-3095 on memory consolidation in the hippocampus: possible involvement ofthe GABAergic system. Peptides 2006; 27: 2307-12.
53. Luft T, Flores DG, Vianna MR, Schwartsmann G, Roesler R, Izquierdo I. A role for hippocampal gastrin-releasing peptide receptors in extinction of aversive memory. Neuroreport 2006; 17: 935-39.
54. Martins MR, Reinke A, Valvassori SS, et al. Non-associative learning and anxiety in rats treated with a single systemic administration of the gastrin-releasing peptide receptor antagonist RC-3095. Peptides 2005; 26: 2525-29.
55. Santo-Yamada Y, Yamada K, Wada E, Goto Y, Wada K. Blockade of bombesin-like peptide receptors impairs inhibitory avoidance learning in mice. Neurosci Lett 2003; 340: 65-68.
56. Mountney C, Sillberg V, Kent P, Anisman H, Merali Z. The role of gastrin-releasing peptide on conditioned fear differential cortical and amygdaloid responses in the rat. Psychopharmacology 2006; 189: 287-296.
57. Venturella R, Lassa D, Luft T, Roozendaal B, Schwartsmann G, Roesler R. Dexamethasone reverses the memory impairment induced by antagonism of hippocampal gastrin-releasing peptide receptors. Peptides 2005; 26: 821-55.
58. Preissler T, Luft T, Kapczinski F, Quevedo, J, Schwartsmann G, Roesler R. Basic fibroblast growth factor prevents the memory impairment induced by gastrin-releasing peptide receptor antagonism in area CA1 of the rat hippocampus. Neurochem Res 2007; DOI: 10.1007/s11064-007-9320-2.
59. Roesler R, Henriques JA, Schwartsmann G. Neuropeptides and anxiety disorders: bombesin receptors as novel therapeutic targets. Trends Pharmacol Sci 2004; 25: 241-42.
60. Presti-Torres J, de Lima MN, Scalco FS, et al. Impairments of social behavior and memory after neonatal gastrin-releasing peptide receptor blockade in rats: Implications for an animal model of neurodevelopmental disorders. Neuropharmacology 2007; 52: 724-32.
61. Meller CA, Henriques JA, Schwartsmann G, Rocaler R. The bombesin/gastrin releasing peptide receptor antagonist RC-3095 blocks apomorphine but not MK-801-induced stereotype in mice. Peptides 2004; 25: 585-88.
62. Clive S, Jodrell D, Webb D. Gastrin-releasing peptide is a potent vasodilator in humans. Clin Pharmacol Ther 2001; 69: 252-59.
63. Gutzwiller P, Drewe J, Hildebrand P, Rossi L, Lauper JZ, Beglinger C. Effect of intravenous human gastrin-releasing peptide on food intake in humans. Gastroenterology 1994; 106: 1168-73.
64. Hildebrand P, Lehmann FS, Ketterer S, et al. Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist. Gut 2001; 49: 23-28.
65. Mulshine JL, Avis I, Treston AM, et al. Clinical use of a monoclonal antibody to bombesin-like peptide in patients with lung cancer. Ann N Y Acad Sci 1988; 547: 360-72.
66. Schwartsmann G, DiLeone LP, Horowitz M, et al. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 2006; 24: 403-12.
67. Kandel, E.R., Shunyatsky, G., Bolshakov, V., Malleret, G.: WO05060625A2 (2005).
68. Schwartsmann, G., Roesler, R., Dal Pizzol, F., Quevedo, J., Kapczinski, F.: US20060160744A1 (2006).
69. Schwartsmann, G., Roesler, R., Dal Pizzol, F., Quevedo, J., Kapczinski, F.: WO06063837A2 (2006).
70. Higuchi K, Kimura O, Furukawa T, Kinoshita H, Iwai N. Bombesin can rescue the enteric ganglia from FK506 neurotoxicity on small bowel transplantation. J Pediatr Surg 2006; 41: 1957-61.
71. Roesler R, Schwartsmann G, Dal Pizzol F. Bombesin protection against FK506 neurotoxicity. J Pediatr Surg 2007; 42: 750.